Natriuretic peptides in clinical practice;Natriuretski peptidi u kliničkoj praksi

Acta Medica Croatica

Volumn 62, Issue 1, 2008, Pages 53-56

  Urek, Roman ^a,b   Čubrilo Turek, Mirjana ^a,b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University Hospital Sveti Duh   (Croatia)

Author keywords

Cardiovascular diseases; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NESIRITIDE; BIOLOGICAL MARKER;

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENDOCRINE SYSTEM; HEART DISEASE; HEART FAILURE; HEART WORK; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; BLOOD; CARDIOVASCULAR DISEASE; PHYSIOLOGY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDES;

EID: 40649118711     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. de Bold AJ, Borenstein HB, Veress AT i sur. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981; 28: 89-94.
2. Suga S, Nakao K, Itoh H i sur. Endotelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of »vascular natriuretic peptide system«. J Clin Invest 1992; 90: 1145-9.
3. Horio T, Tokudome T, Maki T i sur. Gene expression secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003; 144: 2279-84.
4. Silver MA. The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens 2006; 15: 14-21.
5. Wang TJ, Larson MG, Levy D i sur. Impact of age and sex on plasma natriuretic peptide levels in helthy adults. Am J Cardiol 2002; 90: 254-8.
6. Freitag MH, Larson MG, Levy D i sur. Framingham Heart Study. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 2003; 41: 978-83.
7. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 2004; 102: 113-29.
8. Wang TJ, Larson MG, Levy D i sur. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
9. Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circulation 2005; 14: 78-84.
10. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci 2005; 108: 23-36.
11. Maisel AS, McCord J, Nowak RM i sur. Breathing not properly multinational study investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol 2003; 42: 728-35.
12. Wieczorek SJ, Wu AH, Christenson R i sur. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dyfunction and heart failure: a multicenter evaluation. Am Heart J2002; 144: 834-39.
13. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparation of the diagnostic utility of BNP and NT pro BNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004; 341: 41-8.
14. Wright SP, Doughty RN, Pearl A i sur. Plasma ammo-terminal pro-brain natriuretic peptide and accuracy of heart failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42: 793-1800.
15. de Lemos JA, Marrow DA, Bently JH i sur. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
16. Wylie JV, Murphy SA, Morrow DA i sur. Validated risk score predicts the development of congestive heart failure after presentation with unstabile angina or non - ST - elevation myocardial infarction: results from OPUS-TIMI 16 and TRACTIS - TIMI 18. Am Heart J 2004; 148: 173-180.
17. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6: 327-33.
18. MacIntyre K, Capewell S, Stewart S i sur. Evidence of improving prognosis in heart failure. Circulation 2000; 102: 1126-31.
19. Kruger S, Graf J, Merx MW i sur. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147: 60-65.
20. Leuchte HH, Holzapfel M, Baumgartner RA i sur. Clinical significance of brain natriuretic peptide in primary pulmonary hipertension. J Am Coll Cardiol 2004; 43: 764-70.
21. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93: 507-14.
22. Gerber IL, Stewart RA, Legget ME i sur. Increased natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107; 1884-90.
23. Tonimoto K, Yukiiri K, Mizushige K i sur. Usefulness of brain natriuretic peptide as a marker for separating cardiac and noncardiac causes of syncope. Am J Cardiol 2004; 3: 228-30.
24. Richards AM, Lainchbury LG, Troughton RW i sur. Plasma amino-terminal pro-B-type natriuretic peptide predicts postcardioversion reversion to atrial fibrillation. Am J Cardiol 2003; (Suppl A): 99A.
25. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
26. Park MH, Scott RL, Uber PA, Mehra MR. Bedside b-type natriuretic peptide and acute noncellular cardiac allograft rejection. J Heart Lung Trans 2002; 21: 613-14.
27. Ureda R, Yokouchi M, Suzuki T Otomo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 2003; 114: 266-70.
28. Colucci WS, Elkayam U, Horton DP i sur. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Neseridide Study Group. N Engl J Med 2000; 343: 246-53.
29. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003; 107: 2697-2701.
30. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 2004; 93: 237-40.
31. Abraham WT. Neseritide does not increase 30-day or 6-month mortality risk. J Card Fail 2005; 11: 413.
32. Abraham WT, Adams KF, Fonarow GC i sur. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medication: an analysis from the Acute decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57-64.
33. Hayashi M, Tsuatomoto T, Wada A i sur. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-26.
34. Chen HH, Redfield MM, Nordstrom Lj. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004; 10: 115-19.